The Department of Defense's Defense Health Agency awarded a $921,600 Project Grant to The General Hospital Corporation (Massachusetts General Hospital) to research the "Therapeutic Effects of Sulfide Catabolism and Novel Trisulfide Compounds for Amyotrophic Lateral Sclerosis." The grant, under the Military Medical Research and Development program (CFDA 12.420), supports foundational biomedical research aimed at developing novel treatments for amyotrophic lateral sclerosis (ALS). Through this funding, Massachusetts General Hospital will conduct laboratory studies and potentially clinical trials to explore the therapeutic potential of sulfur-containing compounds and their impact on ALS disease progression. The award has a performance period from September 2024 to September 2026.
Generated 1/28/25, 6:58 AM